文献速递神经肌肉病

吉兰-巴雷综合征患者的脑脊液表现与临床特征、亚型及病程的关系

CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.
PubMed 文献 · Neurology · 2023-04-19

基于国际GBS结局研究1500例患者,分析脑脊液表现与临床及电生理亚型、严重程度和结局的关系。脑脊液检查的1231例中846例(70%)显示蛋白细胞分离,且随时间从无力起病增加:≤4天57%,>4天84%。高脑脊液蛋白水平与脱髓鞘亚型、近端或全局性肌无力及第2周和第4周无法跑步的可能性降低相关。

要点

  • 脑脊液蛋白细胞分离在GBS中常见,但蛋白水平正常不能排除该诊断。
  • 高脑脊液蛋白水平与早期严重病程和脱髓鞘亚型相关。
  • 脑脊液细胞数升高罕见≥50个/μL,彻底排除其他诊断后仍可与GBS相符。

核心结论

  • 蛋白细胞分离是GBS的常见表现,但蛋白水平正常不能排除该诊断。
  • 高脑脊液蛋白水平与早期严重病程和脱髓鞘亚型相关。
  • 脑脊液细胞数升高,罕见≥50个/μL,在彻底排除其他诊断后仍可与GBS相符。

研究设计与样本

  • 基于国际GBS结局研究(International GBS Outcome Study)的1500例患者。
  • 蛋白细胞分离定义为蛋白水平升高(>0.45 g/L)且白细胞计数不升高(<50个/μL)。
  • 排除124例(8%)因其他诊断、方案违背或数据不足的患者。
  • 对1231例(89%)患者进行了脑脊液检查。

主要发现

  • 846例(70%)患者脑脊液检查显示蛋白细胞分离,且随时间从无力起病增加:≤4天为57%,>4天为84%。
  • 高脑脊液蛋白水平与脱髓鞘亚型、近端或全局性肌无力相关。
  • 高脑脊液蛋白水平与第2周能够跑步的可能性降低相关(OR 0.42,95% CI 0.25-0.70;p=0.001)。
  • 高脑脊液蛋白水平与第4周能够跑步的可能性降低相关(OR 0.44,95% CI 0.27-0.72;p=0.001)。
  • Miller Fisher综合征、远端为主型无力以及神经传导检查正常或可疑的患者更可能脑脊液蛋白水平较低。

关键数值与推荐

  • 蛋白细胞分离定义:蛋白>0.45 g/L且白细胞计数<50个/μL。
  • 脑脊液细胞数<5个/μL:1005例(83%)。
  • 脑脊液细胞数5-49个/μL:200例(16%)。
  • 脑脊液细胞数≥50个/μL:13例(1%)。
  • 第2周能够跑步的OR 0.42(95% CI 0.25-0.70;p=0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study. METHODS: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL). We excluded 124 (8%) patients because of other diagnoses, protocol violation, or insufficient data. The CSF was examined in 1,231 patients (89%). RESULTS: In 846 (70%) patients, CSF examination showed ACD, which increased with time from weakness onset: ≤4 days 57%, >4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was <5 cells/μL in 1,005 patients (83%), 5-49 cells/μL in 200 patients (16%), and ≥50 cells/μL in 13 patients (1%). DISCUSSION: ACD is a common finding in GBS, but normal protein levels do not exclude this diagnosis. High CSF protein level is associated with an early severe disease course and a demyelinating subtype. Elevated CSF cell count, rarely ≥50 cells/μL, is compatible with GBS after a thorough exclusion of alternative diagnoses. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that CSF ACD (defined by the Brighton Collaboration) is common in patients with GBS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Al-Hakem H, Doets AY, Stino AM, et al. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. Neurology. 2023. PMID: 37076309. doi:10.1212/WNL.0000000000207282

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。